Raphaël Duivenvoorden1, Priya Vart2, Marlies Noordzij2, Augusto C Soares Dos Santos3, Alex B Zulkarnaev4, Casper F M Franssen2, Dirk Kuypers5, Erol Demir6, Hormat Rahimzadeh7, Julia Kerschbaum8, Kitty J Jager9, Kultigin Turkmen10, Marc H Hemmelder11,12, Marcel Schouten13, María Luisa Rodríguez-Ferrero14, Marta Crespo15, Ron T Gansevoort2, Luuk B Hilbrands1. 1. Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands. 2. Department of Internal Medicine, University Medical Center Groningen, Groningen, the Netherlands. 3. Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 4. Surgical Department of Transplantation and Dialysis, Moscow Regional Research and Clinical Institute, Moscow, Russia. 5. Department of Nephrology, University Hospitals Leuven, Leuven, Belgium. 6. Division of Nephrology, Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey. 7. Department of Nephrology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. 8. Austrian Dialysis and Transplant Registry, Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria. 9. ERA-EDTA Registry, Department of Medical Informatics, Amsterdam University Medical Center, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands. 10. Division of Nephrology, Department of Internal Medicine, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey. 11. Division of Nephrology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands. 12. CARIM School for Cardiovascular Disease, University of Maastricht, Maastricht, the Netherlands. 13. Department of Internal Medicine, Tergooi Hospital, Hilversum, the Netherlands. 14. Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 15. Department of Nephrology, Hospital del Mar and& Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Abstract
BACKGROUND: Kidney transplant patients are at high risk for coronavirus disease 2019 (COVID-19)-related mortality. However, limited data are available on longer-term clinical, functional, and mental health outcomes in patients who survive COVID-19. METHODS: We analyzed data from adult kidney transplant patients in the European Renal Association COVID-19 Database who presented with COVID-19 between February 1, 2020, and January 31, 2021. RESULTS: We included 912 patients with a mean age of 56.7 (±13.7) y. 26.4% were not hospitalized, 57.5% were hospitalized without need for intensive care unit (ICU) admission, and 16.1% were hospitalized and admitted to the ICU. At 3 mo follow-up survival was 82.3% overall, and 98.8%, 84.2%, and 49.0%, respectively, in each group. At 3 mo follow-up biopsy-proven acute rejection, need for renal replacement therapy, and graft failure occurred in the overall group in 0.8%, 2.6%, and 1.8% respectively, and in 2.1%, 10.6%, and 10.6% of ICU-admitted patients, respectively. Of the surviving patients, 83.3% and 94.4% reached their pre-COVID-19 physician-reported functional and mental health status, respectively, within 3 mo. Of patients who had not yet reached their prior functional and mental health status, their treating physicians expected that 79.6% and 80.0%, respectively, still would do so within the coming year. ICU admission was independently associated with a low likelihood to reach prior functional and mental health status. CONCLUSIONS: In kidney transplant recipients alive at 3-mo follow-up, clinical, physician-reported functional, and mental health recovery was good for both nonhospitalized and hospitalized patients. Recovery was, however, less favorable for patients who had been admitted to the ICU.
BACKGROUND: Kidney transplant patients are at high risk for coronavirus disease 2019 (COVID-19)-related mortality. However, limited data are available on longer-term clinical, functional, and mental health outcomes in patients who survive COVID-19. METHODS: We analyzed data from adult kidney transplant patients in the European Renal Association COVID-19 Database who presented with COVID-19 between February 1, 2020, and January 31, 2021. RESULTS: We included 912 patients with a mean age of 56.7 (±13.7) y. 26.4% were not hospitalized, 57.5% were hospitalized without need for intensive care unit (ICU) admission, and 16.1% were hospitalized and admitted to the ICU. At 3 mo follow-up survival was 82.3% overall, and 98.8%, 84.2%, and 49.0%, respectively, in each group. At 3 mo follow-up biopsy-proven acute rejection, need for renal replacement therapy, and graft failure occurred in the overall group in 0.8%, 2.6%, and 1.8% respectively, and in 2.1%, 10.6%, and 10.6% of ICU-admitted patients, respectively. Of the surviving patients, 83.3% and 94.4% reached their pre-COVID-19 physician-reported functional and mental health status, respectively, within 3 mo. Of patients who had not yet reached their prior functional and mental health status, their treating physicians expected that 79.6% and 80.0%, respectively, still would do so within the coming year. ICU admission was independently associated with a low likelihood to reach prior functional and mental health status. CONCLUSIONS: In kidney transplant recipients alive at 3-mo follow-up, clinical, physician-reported functional, and mental health recovery was good for both nonhospitalized and hospitalized patients. Recovery was, however, less favorable for patients who had been admitted to the ICU.
Authors: Kenneth Rockwood; Xiaowei Song; Chris MacKnight; Howard Bergman; David B Hogan; Ian McDowell; Arnold Mitnitski Journal: CMAJ Date: 2005-08-30 Impact factor: 8.262
Authors: Johan De Meester; Dirk De Bacquer; Maarten Naesens; Bjorn Meijers; Marie M Couttenye; An S De Vriese Journal: J Am Soc Nephrol Date: 2020-11-05 Impact factor: 10.121
Authors: Olivia S Kates; Brandy M Haydel; Sander S Florman; Meenakshi M Rana; Zohra S Chaudhry; Mayur S Ramesh; Kassem Safa; Camille Nelson Kotton; Emily A Blumberg; Behdad D Besharatian; Sajal D Tanna; Michael G Ison; Maricar Malinis; Marwan M Azar; Robert M Rakita; Jose A Morilla; Aneela Majeed; Afrah S Sait; Mario Spaggiari; Vagish Hemmige; Sapna A Mehta; Henry Neumann; Abbasali Badami; Jason D Goldman; Anuradha Lala; Marion Hemmersbach-Miller; Margaret E McCort; Valida Bajrovic; Carlos Ortiz-Bautista; Rachel Friedman-Moraco; Sameep Sehgal; Erika D Lease; Cynthia E Fisher; Ajit P Limaye Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079